Atria Investments Inc Acquires 2,701 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Atria Investments Inc boosted its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 43.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,853 shares of the medical instruments supplier’s stock after acquiring an additional 2,701 shares during the period. Atria Investments Inc’s holdings in LeMaitre Vascular were worth $822,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in LMAT. NBC Securities Inc. lifted its position in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares during the last quarter. GAMMA Investing LLC boosted its stake in LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 199 shares during the period. USA Financial Formulas bought a new stake in LeMaitre Vascular in the 3rd quarter valued at $60,000. West Oak Capital LLC acquired a new position in LeMaitre Vascular in the 2nd quarter valued at $58,000. Finally, nVerses Capital LLC increased its position in LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $103.55 on Tuesday. The firm has a 50 day simple moving average of $92.11 and a two-hundred day simple moving average of $85.89. LeMaitre Vascular, Inc. has a one year low of $51.70 and a one year high of $106.49. The company has a market cap of $2.33 billion, a P/E ratio of 56.04, a P/E/G ratio of 2.50 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular’s revenue was up 15.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.33 EPS. On average, analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.62%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LMAT. Oppenheimer reissued an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Lake Street Capital started coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 target price on the stock. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target for the company. Barrington Research boosted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Finally, JMP Securities raised their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.